Results 111 to 120 of about 80,955 (206)

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

A transcriptomic-based model associated with PARP inhibitor sensitivity and immunogenic signatures in ovarian cancer. [PDF]

Discov Oncol
Sun X, Li C, Wang Z, Geng J, Wang W, Deng K, Xu Z, Zhao H, Huang D.   +8 more
europepmc   +1 more source

The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review. [PDF]

Front Oncol
Panjarwanto DA, Nabila P, Octavia L, Indrawan IWA, Utomo RP, Permana AY, Kaspan, Adnyana IGHE, Javier RM, Akbar MZH.   +9 more
europepmc   +1 more source

LIPT1 loss confers replication stress and PARP inhibitor sensitivity through PrimPol-mediated ssDNA gaps. [PDF]

Sci Adv
Shang Z, Chiang JC, Hsu CC, Newman C, Davis AJ, Zhang Y.   +5 more
europepmc   +1 more source

Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular Carcinoma. [PDF]

Int J Biol Sci
Li X, Yang S, Zhang M, Guo Z, Wang Y, Meng Y, Liu Y, Zhang H, Xu K, Zhang X, Zhai Y, Jin J, He F, Tian C, Sun A.   +14 more
europepmc   +1 more source

BET inhibition disrupts the FOXM1-MYC axis to induce BRCAness and enhance PARP inhibitor response. [PDF]

NPJ Precis Oncol
Fang P, Saunders A, Minn K, Chua KJ, Brooks RA, Bakke D, Leiserowitz GS, Johnson N, Wang S, Chien J.   +9 more
europepmc   +1 more source

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. [PDF]

J Clin Invest
Köcher S, Elsesy ME, Moustafa A, Mohammadi W, Perugachi Heinsohn A, Nagaraj Y, Oh-Hohenhorst SJ, Hahn J, Siebels B, Mair T, Burdak-Rothkamm S, Tennstedt P, Simon R, Lange T, Tilki D, Frenzel T, Maurer T, Petersen C, Schlüter H, Bokemeyer C, von Amsberg G, Rothkamm K, Mansour WY.   +22 more
europepmc   +1 more source

RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer. [PDF]

Sci Rep
Yoshida H, Li J, Inui H, Rokugawa K, Fujiwara K.   +4 more
europepmc   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

Targeting IP₆ signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance. [PDF]

Nat Commun
Lee SG, Seo Y, Jeong S, Chung Y, Kong S, Kim M, Rhlee JH, Um S, Mathew BP, Maiti S, Kuram MR, Abozeid MA, Park A, Yoo JN, Khim KW, Son K, Amarsanaa E, Kim K, Hong S, Choi J, Park IB, Lee EA, Jeon JH, Park JH, Han JS, Park CY, Kim S, Choi JH, Hong SY, Seo MD, Lee H, Lee JY, Myung K.   +32 more
europepmc   +1 more source